DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR AMIFAMPRIDINE
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Amifampridine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01377922 | A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) | Completed | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2011-06-01 | A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS). |
| NCT02189720 | Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients | Available | Catalyst Pharmaceuticals, Inc. | N/A | 1969-12-31 | The primary objective of the study is: • To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is: • To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus |
| NCT02562066 | Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes | Recruiting | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2016-01-01 | This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment. |
| NCT02970162 | Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) | Enrolling by invitation | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2016-11-01 | This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study. |
| NCT03304054 | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | Not yet recruiting | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2017-12-01 | Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis. |
| NCT03579966 | Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) | Recruiting | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2018-07-01 | Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG. |
| NCT03781479 | Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients | Not yet recruiting | Catalyst Pharmaceuticals, Inc. | Phase 2 | 2019-01-20 | A two-period, two-treatment, crossover study to evaluate the safety, tolerability and efficacy of amifampridine phosphate in ambulatory patients diagnosed with SMA Type 3. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Amifampridine
Clinical Trial Locations for Amifampridine
Trials by Country
Clinical Trial Progress for Amifampridine
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Amifampridine
Sponsor Name
